<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00826644</url>
  </required_header>
  <id_info>
    <org_study_id>CSCLC-0810</org_study_id>
    <nct_id>NCT00826644</nct_id>
  </id_info>
  <brief_title>Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient</brief_title>
  <acronym>COMBAT</acronym>
  <official_title>A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin
      derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators
      will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus
      Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung
      cancer.

      Primary endpoints

        -  to assess Response Rate

      Secondary endpoints

        -  to assess Overall response duration, Time to progression, Overall survival
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the response Rate of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to assess the overall response duration</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the time to progression</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess the overall survival</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Carcinoma, Small Cell</condition>
  <arm_group>
    <arm_group_label>Belotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoposide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belotecan/Cisplatin</intervention_name>
    <description>Belotecan : 0.5mg/㎡/day for Day 1 to 4, Cisplatin : 60mg/㎡/day for Day 1.</description>
    <arm_group_label>Belotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide/Cisplatin</intervention_name>
    <description>Etoposide : 100mg/㎡/day for Day 1 to 3, Cisplatin : 60mg/㎡/day for Day 1. Repeat next cycle at Day 22.</description>
    <arm_group_label>Etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG Performance status 0~2(those with performance status 2 must have been stable with
             no deterioration over the previous 2 weeks)

          -  Histologically or cytologically confirmed small cell lung cancer Patient without
             chemotherapy and radiotherapy

          -  Measurable lesion according to RECIST with at least one measurable lesion not
             previously irradiated, unless disease progression has been documented at that site

          -  Life expectancy of at least 3 months

          -  Provision of written informed consent

        Exclusion Criteria:

          -  As judged by the investigator, any evidence of severe or uncontrolled systemic disease

          -  Serum bilirubin greater than 3 times the upper limit of reference range(ULRR)

          -  Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT)greater
             than 2.5 times ULN if no demonstrable liver metastases (or &gt; 5 times in presence of
             liver metastases)

          -  Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the subject to participate in the study

          -  Pregnancy or breast-feeding women(women of child-bearing potential). Women of
             childbearing potential must practice acceptable methods of birth control to prevent
             pregnancy

          -  Evidence of brain metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jae Oh, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>In-Jae Oh, M.D.,Ph.D.</last_name>
    <phone>82-61-379-7617</phone>
    <email>droij@chonnam.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyu-Sik Kim, M.D.,Ph.D.</last_name>
    <phone>82-61-379-7615</phone>
    <email>cyberkks@chonnam.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun-gun, Jeonnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Jae Oh, M.D.,Ph.D.</last_name>
      <phone>82-61-379-7617</phone>
      <email>droij@chonnam.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2009</study_first_submitted>
  <study_first_submitted_qc>January 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <last_update_submitted>January 9, 2012</last_update_submitted>
  <last_update_submitted_qc>January 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>In-Jae, Oh, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Small cell lung cancer</keyword>
  <keyword>Camptothecin</keyword>
  <keyword>Response rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Belotecan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

